H. Lundbeck A/S
HLUN-A
Rang in Aktien
#2966
H. Lundbeck A/S engages in the research, development, manufacturing, and... H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
Aktienkurs
$7.26
Marktkapitalisierung
$6.08B
Veränderung (1 Tag)
2.66%
Veränderung (1 Jahr)
31.10%
Land
DK
Handel H. Lundbeck A/S (HLUN-A)
Kategorie
Healthcare
Kursverlauf für H. Lundbeck A/S (HLUN-A)
Höchster Schlusskurs: $7.00 am 2026-10-01
Niedrigster Schlusskurs: $4.77 am 2022-06-01
Niedrigster Schlusskurs: $4.77 am 2022-06-01
Kursverlauf der Aktie von H. Lundbeck A/S von 2022 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2026 (TTM) | 6.59% |
| 2025 | 13.54% |
| 2024 | 13.71% |
| 2023 | 20.95% |
| 2022 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $63.71 | 72.92% |
US
|
|
| $45.98 | 36.92% |
SE
|
|
| $172.16 | 24.48% |
FR
|
|
| $59.52 | -0.48% |
IT
|
|
| $108.82 | 47.75% |
US
|
